[1] |
Hayreh SS. Neovascular glaucoma[J]. Prog Retin Eye Res,2007,26(5):470-485.
|
[2] |
Zhou M, Chen S, Wang W, et al. Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab[J].Invest Ophthalmol Vis Sci,2013,54(6):3874-3879.
|
[3] |
Zhou M, Wang J, Wang W,et al. Placenta Growth Factor in Eyes with Neovascular Glaucoma Is Decreased after Intravitreal Ranibizumab Injection[J].PLoS One,2016,11(1):e146993.
|
[4] |
Sims JN, Lawler J.Thrombospondin-1-Based Antiangiogenic Therapy[J].J Ocul Pharmacol Ther,2015,31(7):366-370.
|
[5] |
Weiss DI, Shaffer RN, Nehrenberg TR. Neovascular gluacoma complicating carotid-cavernous fistula[J].Arch Ophthalmol,1963,69(69):304-307.
|
[6] |
Lorenz K, Scheller Y, Bell K,et al.A prospective,randomised,placebo-controlled,double-masked,three-armed,multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma-the STRONG study:study protocol for a randomised controlled trial[J].Trials,2017,18(1):128.
|
[7] |
Moraczewski AL, Lee RK, Palmberg PF,et al.Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab[J].Br J Ophthalmol,2009,93(5):589-593.
|
[8] |
Degoumois A, Miocque S, Denion E.Central retinal artery occlusion without underlying chronic ocular ischemic syndrome may lead to neovascular glaucoma[J].J Fr Ophtalmol,2017,40(9):758-762.
|
[9] |
An TS, Kwon SI.Neovascular glaucoma due to branch retinal vein occlusion combined with branch retinal artery occlusion[J].Korean J Ophthalmol,2013,27(1):64-67.
|
[10] |
Kim YH, Sung MS, Park SW.Clinical Features of Ocular Ischemic Syndrome and Risk Factors for Neovascular Glaucoma[J].Korean J Ophthalmol,2017,31(4):343-350.
|
[11] |
Riechardt AI, Pilger D, Cordini D,et al.Neovascular glaucoma after proton beam therapy of choroidal melanoma:incidence and risk factors[J].Graefes Arch Clin Exp Ophthalmol,2017,255(11):2263-2269.
|
[12] |
Konareva-Kostianeva M.Neovascular glaucoma[J].Folia Med (Plovdiv),2005,47(2):5-11.
|
[13] |
Vieira-Potter VJ, Karamichos D, Lee DJ.Ocular Complications of Diabetes and Therapeutic Approaches[J].Biomed Res Int,2016,2016(3):1-14.
|
[14] |
Yang H, Yu X, Sun X.Neovascular glaucoma:Handling in the future[J].Taiwan J Ophthalmol,2018,8(2):60-66.
|
[15] |
Tsai JC, Feuer WJ, Parrish RN,et al.5-Fluorouracil filtering surgery and neovascular glaucoma.Long-term follow-up of the original pilot study[J].Ophthalmology,1995,102(6):887-893.
|
[16] |
Mermoud A, Salmon JF, Alexander P,et al.Molteno tube implantation for neovascular glaucoma.Long-term results and factors influencing the outcome[J].Ophthalmology,1993,100(6):897-902.
|
[17] |
Liu L, Xu Y, Huang Z,et al.Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma:assessment of efficacy and complications[J].BMC Ophthalmol,2016,16(1):65.
|
[18] |
Abe RY, Shigueoka LS, Vasconcellos JPC,et al.Primary Trabeculectomy Outcomes by Glaucoma Fellows in a Tertiary Hospital in Brazil[J].J Glaucoma,2017,26(11):1019-1024.
|
[19] |
Gedde SJ, Singh K, Schiffman JC,et al.The Tube Versus Trabeculectomy Study:interpretation of results and application to clinical practice[J].Curr Opin Ophthalmol,2012,23(2):118-126.
|
[20] |
Gedde SJ, Schiffman JC, Feuer WJ,et al.Three-year follow-up of the tube versus trabeculectomy study[J].Am J Ophthalmol,2009,148(5):670-684.
|
[21] |
Kwon HJ, Kong Y, Tao LW,et al.Surgical outcomes of trabeculectomy and glaucoma drainage implant for uveitic glaucoma and relationship with uveitis activity[J].Clin Exp Ophthalmol,2017,45(5):472-480.
|
[22] |
Tan AN, Cornelissen MF, Webers CAB,et al.Outcomes of severe uveitic glaucoma treated with Baerveldt implant:can blindness be prevented?[J].Acta Ophthalmol,2018,96(1):24-30.
|
[23] |
Sasamoto Y, Oshima Y, Miki A,et al.Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma:a retrospective two-dose comparative study[J].J Ocul Pharmacol Ther,2012,28(1):41-48.
|
[24] |
Zhou M, Xu X, Zhang X,et al.Clinical Outcomes of Ahmed Glaucoma Valve Implantation With or Without Intravitreal Bevacizumab Pretreatment for Neovascular Glaucoma:A Systematic Review and Meta-Analysis[J].J Glaucoma,2016,25(7):551-557.
|
[25] |
Wakabayashi T, Oshima Y, Sakaguchi H,et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases[J].Ophthalmology,2008,115(9):1571-1581.
|
[26] |
Ishibashi S, Kondo H.Effect of Intravitreal Bevacizumab Injection on Iris and Iridocorneal Angle Neovascularization in Neovascular Glaucoma[J].J UOEH,2015,37(4):299-304.
|
[27] |
Davidorf FH, Mouser JG, Derick RJ.Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection[J].Retina,2006,26(3):354-356.
|
[28] |
Vásquez LM, Somani S, Altomare F,et al.Intracameral bevacizumab in the treatment of neovascular glaucoma and exudative retinal detachment after brachytherapy in choroidal melanoma[J].Can J Ophthalmol,2009,44(1):106-107.
|
[29] |
Iliev ME, Domig D, Wolf-Schnurrbursch U,et al.Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma[J].Am J Ophthalmol,2006,142(6):1054-1056.
|
[30] |
Lee SJ, Lee JJ, Kim SY,et al.Intravitreal bevacizumab(Avastin)treatment of neovascular glaucoma in ocular ischemic syndrome[J].Korean J Ophthalmol,2009,23(2):132-134.
|
[31] |
Kahook MY, Schuman JS, Noecker RJ.Intravitreal bevacizumab in a patient with neovascular glaucoma[J].Ophthalmic Surg Lasers Imaging,2006,37(2):144-146.
|
[32] |
Kim ES, Yu SY, Han SB,et al.Decompression retinopathy after intravitreal bevacizumab and anterior chamber paracentesis in a patient with neovascular glaucoma[J].Indian J Ophthalmol,2016,64(11):861-863.
|
[33] |
Mason JR, Albert MJ, Mays A,et al.Regression of neovascular iris vessels by intravitreal injection of bevacizumab[J].Retina,2006,26(7):839-841.
|
[34] |
Arcieri ES, Paula JS, Jorge R,et al.Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation:2-year follow-up[J].Acta Ophthalmol,2015,93(1):e1-6.
|
[35] |
Silva PJ, Jorge R, Alves CR,et al.Short-term results of intravitreal bevacizumab(Avastin)on anterior segment neovascularization in neovascular glaucoma[J].Acta Ophthalmol Scand,2006,84(4):556-557.
|
[36] |
Sothornwit N.Intravitreal bevacizumab for ahmed glaucoma valve implantation in neovascular glaucoma:a case report[J].J Med Assoc Thai,2008,91(Suppl 1):S162-165.
|
[37] |
Gheith ME, Siam GA, de Barros DS,et al.Role of intravitreal bevacizumab in neovascular glaucoma[J].J Ocul Pharmacol Ther,2007,23(5):487-491.
|
[38] |
Marey HM, Ellakwa AF.Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma[J].Clin Ophthalmol,2011,5(1):841-845.
|
[39] |
Yazdani S, Hendi K, Pakravan M,et al.Intravitreal bevacizumab for neovascular glaucoma:a randomized controlled trial[J].J Glaucoma,2009,18(8):632-637.
|
[40] |
Cheema RA, Al-Mubarak MM, Amin YM,et al.Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy:prospective randomized study[J].J Cataract Refract Surg,2009,35(1):18-25.
|
[41] |
Chen S, Zhou M, Wang W,et al.Levels of angiogenesis-related vascular endothelial growth factor family in neovascular glaucoma eyes[J].Acta Ophthalmol,2015,93(7):e556-e560.
|
[42] |
Andrés-Guerrero V, Perucho-González L, García-Feijoo J,et al.Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma[J].Adv Ther,2017,34(2):378-395.
|
[43] |
Adams JC, Tucker RP.The thrombospondin type 1 repeat (TSR) superfamily:diverse proteins with related roles in neuronal development[J].Dev Dyn,2000,218(2):280-299.
|
[44] |
Tucker RP.The thrombospondin type 1 repeat superfamily[J].Int J Biochem Cell Biol,2004,36(6):969-974.
|
[45] |
Adams JC.Thrombospondin-1[J].Int J Biochem Cell Biol,1997,29(6):861-865.
|
[46] |
Nunes SS, Outeiro-Bernstein MA, Juliano L,et al.Syndecan-4 contributes to endothelial tubulogenesis through interactions with two motifs inside the pro-angiogenic N-terminal domain of thrombospondin-1[J].J Cell Physiol,2008,214(3):828-837.
|
[47] |
Iruela-Arispe ML, Lombardo M, Krutzsch HC,et al.Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats[J].Circulation,1999,100(13):1423-1431.
|
[48] |
Shinkaruk S, Bayle M, Lain G,et al.Vascular endothelial cell growth factor(VEGF),an emerging target for cancer chemotherapy[J].Curr Med Chem Anticancer Agents,2003,3(2):95-117.
|
[49] |
Good DJ, Polverini PJ, Rastinejad F,et al.A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin[J].Proc Natl Acad Sci USA,1990,87(17):6624-6628.
|
[50] |
Suzuma K, Takagi H, Otani A,et al.Expression of thrombospondin-1 in ischemia-induced retinal neovascularization[J].Am J Pathol,1999,154(2):343-354.
|
[51] |
Flugel-Koch C, Ohlmann A, Fuchshofer R,et al.Thrombospondin-1 in the trabecular meshwork:localization in normal and glaucomatous eyes,and induction by TGF-beta1 and dexamethasone in vitro[J].Exp Eye Res,2004,79(5):649-663.
|
[52] |
Shen J, Choy DF, Yoshida T,et al.Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF[J].J Cell Physiol,2014,229(8):974-983.
|
[53] |
Hiscott P, Seitz B, Schlotzer-Schrehardt U,et al.Immunolocalisation of thrombospondin 1 in human,bovine and rabbit cornea[J].Cell Tissue Res,1997,289(2):307-310.
|
[54] |
Cursiefen C, Masli S, Ng TF,et al.Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis[J].Invest Ophthalmol Vis Sci,2004,45(4):1117-1124.
|
[55] |
Chan CK, Pham LN, Zhou J,et al.Differential expression of pro- and antiangiogenic factors in mouse strain-dependent hypoxia-induced retinal neovascularization[J].Lab Invest,2005,85(6):721-733.
|
[56] |
Sheibani N, Sorenson CM, Cornelius LA,et al.Thrombospondin-1,a natural inhibitor of angiogenesis,is present in vitreous and aqueous humor and is modulated by hyperglycemia[J].Biochem Biophys Res Commun,2000,267(1):257-261.
|
[57] |
Hiscott P, Paraoan L, Choudhary A,et al.Thrombospondin 1, thrombospondin 2 and the eye[J].Prog Retin Eye Res,2006,25(1):1-18.
|
[58] |
Wang S, Gottlieb JL, Sorenson CM,et al.Modulation of thrombospondin 1 and pigment epithelium-derived factor levels in vitreous fluid of patients with diabetes[J]. Arch Ophthalmol,2009,127(4):507-513.
|
[59] |
Elahy M, Baindur-Hudson S, Cruzat VF,et al.Mechanisms of PEDF-mediated protection against reactive oxygen species damage in diabetic retinopathy and neuropathy[J].J Endocrinol,2014,222(3):R129-139.
|
[60] |
Young BR, Doyle MJ, Collins WE,et al.Effect of thrombospondin and other platelet alpha-granule proteins on artificial surface-induced thrombosis[J].Trans Am Soc Artif Intern Organs,1982,28(1):498-503.
|
[61] |
Chowers I, Liu D, Farkas RH,et al.Gene expression variation in the adult human retina[J].Hum Mol Genet,2003,12(22):2881-2893.
|
[62] |
Shaw AC, Hennekam RC.Interpreting humanity's genes[J].Eur J Med Genet,2009,52(6):379-380.
|
[63] |
Chowers I, Gunatilaka TL, Farkas RH,et al.Identification of novel genes preferentially expressed in the retina using a custom human retina cDNA microarray[J].Invest Ophthalmol Vis Sci,2003,44(9):3732-3741.
|